How to choose a booster shot

Tina Hesman Saey, Science News
By Tina Hesman Saey, Science News
Nov. 20, 2021

It’s been a little over six months since I got my second dose of the COVID-19 vaccine from Pfizer and its German partner BioNTech, and a phone call from my state health department over the weekend reminded me that I am eligible for a booster. But do I really need to get a third COVID-19 shot? If so, which of the three authorized or approved vaccines available in the United States should I get? To make my decision, I looked at the evidence and talked to some experts. What I found out could be useful to anyone deciding on a booster.

Now that people can mix and match COVID-19 vaccines, choosing one for a booster
dose may be complicated. Reviewing the data on and talking to scientists about
the vaccines from Pfizer/BioNTech, Moderna, Johnson & Johnson and AstraZeneca
(not available in the United States) can help inform that decision.

Let’s start with Johnson & Johnson. Everyone who got that shot as their initial vaccine is recommended to get a booster, U.S. health officials and experts say (SN: 10/19/21). That’s because the antibody response from that one-dose vaccine isn’t as high as for the two-dose mRNA vaccines from Pfizer and Moderna, and it is waning. “It doesn’t go away entirely,” says Sachin Nagrani, medical director of Heal, a company that provides primary health care in people’s homes via telehealth visits and house calls. But a few months after the J&J shot, “it seems like your immune response is less protective.” 

There are few studies on J&J boosters, but the AstraZeneca vaccine, which is built on similar technology but not available in the United States, could provide some clues (SN: 11/23/20; SN: 2/27/21). Both vaccines use adenoviruses to deliver DNA instructions for building the coronavirus’s spike protein to cells. Studies show combining AstraZeneca’s COVID-19 vaccine with a boost from the Pfizer shot (or sometimes Moderna) was more effective than getting another dose of AstraZeneca. 

For instance, in Sweden, a double dose of AstraZeneca was about 50 percent effective at preventing symptomatic illness. But AstraZeneca followed by Pfizer was 67 percent effective and AstraZeneca boosted with Moderna was 79 effective, researchers reported October 18 in the Lancet Regional Health – Europe

A preliminary study that mixed and matched vaccines in the United States found that people who got J&J as their first dose developed much higher levels of antibodies if their second dose was an mRNA vaccine than if it was another jab of J&J. Those data suggest that people who got vaxxed with J&J should consider getting an mRNA booster.

For people like me who got an mRNA vaccine in the first go-around, choosing a booster is a bit more complicated. Boosters are recommended for people 65 and older, but I’m younger than that. People who have a high chance of getting exposed to COVID-19 through their jobs or living situations can also get a booster. But right now I work from home, where just my husband and I live. People with underlying health conditions that put them at greater risk of severe disease are also eligible. I do have a couple of health conditions that make me more vulnerable. But how much more benefit would I get from a booster shot than from the two doses I already received?

Much of what we know about mRNA booster shots comes from data collected in Israel, where everyone 12 and older has been eligible for a third dose of the Pfizer vaccine since the end of August. People who were fully vaccinated with two doses of the vaccine and had no underlying health risks, had a very low chance of developing severe COVID-19 or needing to be admitted to a hospital: Just 3.1 of every 100,000 healthy people who had gotten two doses of vaccine got severe disease, researchers reported October 29 in the Lancet

But with underlying health risks, that number started to climb. Of every 100,000 fully vaccinated people with one or two health risks, 82 developed severe disease. And with three or more health risks, the rate was 113 of every 100,000 people. Getting a booster dropped the severe disease rate for those with one or two health conditions to 3.2 per 100,000 and cut the rate by a bit more than half — to 51.6 per 100,000 — for those with three or more health conditions. That evidence leads me to think a booster is in order for me.

For young, healthy people the risk equation may be different. Nagrani says it’s OK for people in that situation to wait a while for more data on the vaccine’s longevity before getting a booster. But people 65 and older and those with health conditions or who live in assisted-living facilities should probably get a booster now.

The next question is which shot should I get? It’s now fine to mix and match vaccine doses for booster shots. I could stick with Pfizer, or switch to Moderna or J&J. The first thing I’m considering is: What’s my goal? While I would like to not get infected with COVID-19 at all, that’s maybe not so realistic. None of the COVID-19 vaccines produce “sterilizing immunity,” which protects you from getting infected. But they all provide protection against illness.

At first glance, it looks as if the mRNA vaccines are the way to go, but I’ve been intrigued by discussions in the recent advisory board meetings for the U.S. Food and Drug Administration and Centers for Disease Control and Prevention about different types of immunity produced by the vaccines. The mRNA vaccines give gangbuster levels of neutralizing antibodies, which help keep the coronavirus from infecting cells. But adenovirus-based vaccines like J&J’s and AstraZeneca’s seem to be better at revving up long-lasting protection from immune cells called T cells. And some evidence suggests that a combo of an mRNA vaccine with an adenovirus-based vaccine like J&J’s could have some advantages. 

In a study in France, participants got either two doses of the Pfizer vaccine or a dose of AstraZeneca with a Pfizer chaser. People who got Pfizer for both doses were twice as likely to get infected with the coronavirus as those who got the mixed doses, researchers reported October 21 in Nature. That was 10 infections among the 2,512 (0.39 percent) who got the mixed doses, compared with 81 infections among the 10,609 people (0.76 percent) who got Pfizer alone.  

I asked one of that study’s coauthors, Jacqueline Marvel, an immunologist at the International Center for Infectious Disease Research (CIRI) in Lyon, France, about whether I should switch to J&J for my booster shot to give my T cells a lift or stick with an mRNA vaccine. “I’m not sure you want to change the vaccine just for increasing the T cell response,” she said. That answer surprised me a little because Marvel studies T cells for a living. 

“I’m pro T cell,” she said. But “neutralizing antibodies are what you want to have first. The antibodies stop the virus from getting into the cells and protect you much earlier than the T cells would,” Marvel explained. “If people don’t want to be ill and have symptoms, you want the antibodies.” And to maximize antibodies, the mRNA vaccines are the way to go.

Side effects from the booster doses are similar to those experienced from earlier doses, though some data suggest the effects after a booster may be milder than after the second dose. Some people are worried about rare side effects such as myocarditis, an inflammation of the heart muscle, that has sometimes happened after an mRNA dose, particularly for young males after the second dose. But that side effect is uncommon: Just 17 out of 2.5 million people who got a Pfizer booster shot in Israel developed myocarditis or pericarditis, Israeli health officials reported (SN: 10/19/21). I’m not a young man and my first two doses produced only a sore arm, so side effects aren’t a big concern for me.

All of this convinced me to get an mRNA shot. But which one? That decision came down to convenience. I got online and searched for places where I could get my booster. It turns out that few of the grocery stores, pharmacies or other vaccine providers in my area offer the Moderna vaccine (even fewer have the J&J shot), but Pfizer doses are plentiful. So I got a Pfizer booster in my right arm and a flu vaccine in the left. (It’s safe to take both at the same time.) According to the CDC, I’m not alone. Almost 99 percent of people fully vaccinated with Pfizer also chose Pfizer for their booster

My arms might ache for a little while, but that’s a price I’m more than willing to pay to avoid severe illness for myself and to help protect those around me from getting infected.

This story was originally published by Science News, a nonprofit independent news organization.

Enjoy reading ASBMB Today?

Become a member to receive the print edition monthly and the digital edition weekly.

Learn more
Tina Hesman Saey, Science News
Tina Hesman Saey, Science News

Tina Hesman Saey is a geneticist-turned-science writer who covers all things microscopic and a few too big to be viewed under a microscope. She is an honors graduate of the University of Nebraska-Lincoln where she did research on tobacco plants and ethanol-producing bacteria.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Opinions

Opinions highlights or most popular articles

Learning to listen

Learning to listen

May 9, 2024

In her talk at DiscoverBMB, ASBMB Sustained Leadership Award recipient Adele Wolfson reflected on the increased inclusiveness of science in recent decades.

Getting to know scientists half a world away

Getting to know scientists half a world away

April 24, 2024

In a program at Wellesley College, students interview and write about researchers at a university in Ghana.

Let’s make ASBMB awardees look more like BMB scientists

Let’s make ASBMB awardees look more like BMB scientists

April 23, 2024

Think about nominating someone outside your immediate network.

A paleolithic peer review

A paleolithic peer review

April 18, 2024

You might think review panels have only been around for the last century or so. You would be mistaken.

Early COVID-19 research is riddled with poor methods and low-quality results

Early COVID-19 research is riddled with poor methods and low-quality results

April 13, 2024

The pandemic worsened, but didn’t create, this problem for science.

So, you went to a conference. Now what?
Professional Development

So, you went to a conference. Now what?

April 12, 2024

Once you return to normal lab life, how can you make use of everything you learned?